CORT

Bragar Eagel & Squire, P.C. Is Investigating Enochian, Corcept, Rollins, and Target and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 16, 2022
SEC, News, U.S. Securities and Exchange Commission, Rollins, Review, GLOBE, United, Income, NYSE, Corcept Therapeutics, Record, District, Health Insurance Portability and Accountability Act, Documentation, NASDAQ, Sale, Company, HIPAA, TGT, Death, Target Corporation, Annual report, Accountability Act, Period. End of Sentence., Target, CORT, Private investigator, Online gambling, Audit, Renewable energy, Enochian, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022.
  • Dr. Gumrukcu sold 253,493 shares of Enochian stock on May 18, 2022, for a total value of over $2 million.
  • For more information on the Target investigation go to: https://bespc.com/cases/TGT
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Rollins, Target, and TG Therapeutics and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, July 11, 2022
Target, TGT, FDA, Chronic lymphocytic leukemia, News, Adult, Regulation of tobacco by the U.S. Food and Drug Administration, Oncology Drug Advisory Committee, Umbralisib, Therapy, Lymphocytosis, Rollins, District, NYSE, Shanda, Documentation, Food, CLL, TG, Record, Company, SLL, Period. End of Sentence., U.S. Securities and Exchange Commission, HIPAA, ODAC, Income, Health Insurance Portability and Accountability Act, Corcept Therapeutics, Review, Sale, GLOBE, Accountability Act, Patient, SEC, Follicular lymphoma, BLA, Target Corporation, Annual report, NASDAQ, CORT, Online gambling, Audit, Renewable energy, Medical device, U2, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, TG Therapeutics' stock price fell $8.16 per share, or 34.93%, to close at $15.20 per share on November 30, 2021.
  • For more information on the TG Therapeutics investigation go to: https://bespc.com/cases/TGTX
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Enochian, Corcept, Rollins, and Target and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, July 5, 2022
Documentation, Review, CORT, Annual report, Death, Period. End of Sentence., TGT, Corcept Therapeutics, U.S. Securities and Exchange Commission, Target, GLOBE, Accountability Act, Sale, Company, Health Insurance Portability and Accountability Act, Record, HIPAA, United, District, NYSE, Rollins, SEC, NASDAQ, News, Income, Target Corporation, Private investigator, Online gambling, Audit, Renewable energy, Enochian, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022.
  • Dr. Gumrukcu sold 253,493 shares of Enochian stock on May 18, 2022, for a total value of over $2 million.
  • For more information on the Target investigation go to: https://bespc.com/cases/TGT
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating Agrify, Carvana, Enochian, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 30, 2022
CORT, Death, Corcept Therapeutics, GLOBE, Accountability Act, Sale, Company, U.S. Securities and Exchange Commission, Health Insurance Portability and Accountability Act, Record, HIPAA, United, District, NYSE, Carvana, NASDAQ, News, Therapy, Online gambling, Animal, Audit, Enochian, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Agrifys common stock price fell sharply during intraday trading on December 16, 2021.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer

Retrieved on: 
Wednesday, June 29, 2022
Weight gain, Oncology, CORT, Clinical Oncology, Patient, Probability, GLOBE, COVID-19, Union, Progression-free survival, Ovarian cancer, Disease, Goal, Intellectual property, Pancreatic cancer, Immune system, Publication, Woman, Liver disease, Cancer, Food, Doctor of Pharmacy, GR, Survival, SEC, NASDAQ, Paralympic record progression track cycling – Women's 1 km time trial, Recurrence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intention, Pharmaceutical industry, Medical imaging, Hospital, Corcept Therapeutics

The 20,000 women in the United States and an equal number in Europe with platinum-resistant ovarian cancer have few good treatment options.

Key Points: 
  • The 20,000 women in the United States and an equal number in Europe with platinum-resistant ovarian cancer have few good treatment options.
  • ROSELLA has a planned enrollment of 360 women with recurrent, platinum-resistant ovarian cancer, randomized 1:1 to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel monotherapy.
  • Additional information about ROSELLA and Corcepts Phase 2 trial results can be found at the publications and press releases tabs of www.corcept.com.
  • Corcept is studying relacorilant in a variety of serious disorders, including ovarian and adrenal cancer and Cushings syndrome.

Bragar Eagel & Squire, P.C. Is Investigating Unity, Carvana, Enochian, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, June 25, 2022
CORT, Death, Corcept Therapeutics, IDFA, GLOBE, Accountability Act, Growth, Sale, Company, Unity Technologies, U.S. Securities and Exchange Commission, Health Insurance Portability and Accountability Act, Record, HIPAA, United, District, NYSE, Carvana, Transformers: Generation 1, NASDAQ, Unity, News, Therapy, Online gambling, Video game, Renewable energy, Audit, Enochian, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On May 10, 2022, after the market closed, Unity announced its first quarter 2022 financial results.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Carvana, Enochian, Corcept, and Clariant and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, June 20, 2022
United, Fraud, HIPAA, Corcept Therapeutics, Company, U.S. Securities and Exchange Commission, CORT, NASDAQ, Record, News, Sale, Health Insurance Portability and Accountability Act, District, Death, Carvana, Accountability Act, NYSE, GLOBE, Online gambling, Audit, P.C, Enochian, Clariant

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, shares of Clariant AG ADR shares fell more than 14% in intraday trading on February 14, 2022.
  • For more information on the Clariant investigation go to: https://bespc.com/cases/CLZNY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Carvana, Enochian, Novartis, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, June 14, 2022
Company, Health Insurance Portability and Accountability Act, CORT, HIPAA, Food, United, News, Record, Carvana, U.S. Securities and Exchange Commission, Sale, Therapy, GLOBE, NVS, NYSE, Novartis, NASDAQ, District, Accountability Act, Corcept Therapeutics, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Website, Online gambling, Renewable energy, Audit, Enochian, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Carvanas stock price fell $6.55 per share, or 15.75%, to close at $35.05 per share on May 18, 2022.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022.
  • On this news, Novartis stock fell $2.06, or 2.3%, to close at $86.21 on May 5, 2022, thereby injuring investors.

Bragar Eagel & Squire, P.C. Is Investigating Carvana, Enochian, Novartis, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 9, 2022
Company, Health Insurance Portability and Accountability Act, CORT, HIPAA, Food, United, News, Record, Carvana, U.S. Securities and Exchange Commission, Sale, Therapy, GLOBE, NVS, NYSE, Novartis, NASDAQ, District, Accountability Act, Corcept Therapeutics, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Website, Renewable energy, Audit, Online gambling, Enochian, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Carvanas stock price fell $6.55 per share, or 15.75%, to close at $35.05 per share on May 18, 2022.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022.
  • On this news, Novartis stock fell $2.06, or 2.3%, to close at $86.21 on May 5, 2022, thereby injuring investors.

Bragar Eagel & Squire, P.C. Is Investigating Verrica, Gap, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, June 4, 2022
Woman, CMO, Company, Dermatology, LLC, Rest, Old Navy, CORT, HIPAA, Health Insurance Portability and Accountability Act, Molluscum contagiosum, Food, News, Clothing, Endpoint security, Record, Therapy, The Wall Street Journal, U.S. Securities and Exchange Commission, Gap Inc., Sale, FDA, GLOBE, Gap, NYSE, NASDAQ, District, Skin, GPS, Accountability Act, Corcept Therapeutics, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Online gambling, Pharmaceutical industry, Audit, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Verrica is a dermatology therapeutics company that develops and commercializes treatments for people with skin diseases in the United States.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.